Citigroup
CURX

Citigroup’s Curanex Pharmaceuticals CURX Stock Holding History

Citigroup’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.88K Buy
+19,332
New +$7.26K ﹤0.01% 5046

Other funds holding CURX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's CURX Position: Q1 2026 in Review

Citigroup opened a new position in Curanex Pharmaceuticals (CURX) in Q1 2026: 19,332 shares worth $9.88K. The stake represents ﹤0.01% of the portfolio and ranks #5046 among its holdings.

8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

  • Citigroup held 19,332 shares of Curanex Pharmaceuticals worth $9.88K as of Q1 2026.
  • Curanex Pharmaceuticals was a new Citigroup position in Q1 2026.
  • Curanex Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5046 holding.
  • 8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.